PE17895A1 - Antagonista triciclico diacepinico de vasopresina y antagonista de oxitocina - Google Patents

Antagonista triciclico diacepinico de vasopresina y antagonista de oxitocina

Info

Publication number
PE17895A1
PE17895A1 PE1994247526A PE24752694A PE17895A1 PE 17895 A1 PE17895 A1 PE 17895A1 PE 1994247526 A PE1994247526 A PE 1994247526A PE 24752694 A PE24752694 A PE 24752694A PE 17895 A1 PE17895 A1 PE 17895A1
Authority
PE
Peru
Prior art keywords
opt
antagonist
substd
satd
tricyclic
Prior art date
Application number
PE1994247526A
Other languages
English (en)
Inventor
Guillermo Delos Santos Efren
Fred Reich Marvin
Donald Albright Jay
Sum Fuk-Wah
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of PE17895A1 publication Critical patent/PE17895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE: 1) Y ES -CH(ALQUILO C1-C3)-, -CO-, -(CH2)n, VARIANDO n DE 0 A 2; 2) A-B SE SELECCIONA DE -(CH2)m-N(R3)-, -N(R3)-(CH2)m, VARIANDO m DE 1 A 2; 3) LA PORCION QUE CONTIENE A Z PUEDE SER UN FENILO FUSIONADO, UN ANILLO HETEROCICLICO AROMATICO DE 5 A 6 MIEMBROS CON 2 ATOMOS DE NITROGENO o UN ANILLO DE 5 MIEMBROS CON NITROGENO, OXIGENO o AZUFRE; 4) D, E, F PUEDEN SER CARBONO o NITROGENO Y EL ANILLO PUEDE ESTAR SUSTITUIDO; 5) R3 ES -CO-ARILO, SIENDO EL ARILO UN FENILO, INDOL o HETEROCICLO DE 5 MIEMBROS OPCIONALMENTE SUSTITUIDO; EL CUAL PUEDE SER ANTAGONISTA DE VASOPRESINA Y OXITOCINA
PE1994247526A 1993-07-29 1994-07-26 Antagonista triciclico diacepinico de vasopresina y antagonista de oxitocina PE17895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10000493A 1993-07-29 1993-07-29

Publications (1)

Publication Number Publication Date
PE17895A1 true PE17895A1 (es) 1995-07-18

Family

ID=22277643

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1994247526A PE17895A1 (es) 1993-07-29 1994-07-26 Antagonista triciclico diacepinico de vasopresina y antagonista de oxitocina

Country Status (29)

Country Link
US (2) US5516774A (es)
EP (1) EP0636625B1 (es)
JP (1) JP3782475B2 (es)
KR (1) KR100347479B1 (es)
CN (2) CN1039908C (es)
AT (1) ATE176234T1 (es)
AU (1) AU683660B2 (es)
BR (1) BR1100563A (es)
CA (1) CA2128956C (es)
CZ (1) CZ291322B6 (es)
DE (1) DE69416211T2 (es)
DK (1) DK0636625T3 (es)
EC (1) ECSP941137A (es)
ES (1) ES2129090T3 (es)
FI (3) FI110944B (es)
GR (1) GR3030069T3 (es)
HK (1) HK1011363A1 (es)
HU (1) HU220707B1 (es)
IL (1) IL110435A (es)
LV (1) LV12497B (es)
NO (1) NO301827B1 (es)
NZ (1) NZ264115A (es)
PE (1) PE17895A1 (es)
PH (1) PH31469A (es)
PL (1) PL178563B1 (es)
RU (1) RU2126006C1 (es)
SG (1) SG47522A1 (es)
SK (1) SK280836B6 (es)
ZA (1) ZA945603B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733905A (en) * 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5889001A (en) * 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5968930A (en) * 1993-07-29 1999-10-19 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
AR002459A1 (es) * 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5880122A (en) * 1996-11-01 1999-03-09 American Home Products Corporation 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines
HUP9904514A3 (en) * 1996-11-01 2000-10-30 Wyeth Corp 5h-pyrrolo[2,1-c][1,4]-benzodiazepin 3-carboxamide derivatives, process for their preparation, their use and pharmaceutical compositions containing them
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US6194407B1 (en) 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
ES2229525T3 (es) * 1997-07-30 2005-04-16 Wyeth Agonistas triciclicos de la vasopresina.
AR018818A1 (es) * 1998-04-03 2001-12-12 Yamano Masaki Una composicion farmaceutica para la terapia de un edema.
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
ES2207333T7 (es) * 1999-01-19 2009-06-18 Orto-Mcneil Pharmaceutical, Inc. Benzodiazepinas triciclicas utilizadas como antagonistas del receptor de la vasopresina.
US6620807B1 (en) 1999-02-04 2003-09-16 Wyeth Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
US6344451B1 (en) 1999-02-04 2002-02-05 American Home Products Pyrrolobenzodiazepine carboxyamide vasopressin agonists
US6297234B1 (en) 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
US6235900B1 (en) 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
CN1339037A (zh) * 1999-02-04 2002-03-06 美国家用产品公司 吡咯并苯并二吖庚因酰胺血管加压素激动剂
CA2388474A1 (en) * 1999-09-27 2001-04-05 American Cyanamid Company Vasopressin antagonist formulation and process
US6352718B1 (en) 1999-09-27 2002-03-05 American Cyanamid Company Vasopressin antagonist formulation and process
US6420358B1 (en) 1999-09-27 2002-07-16 American Cyanamid Company Vasopressin antagonist and diuretic combination
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
EP1277729A4 (en) * 2000-04-28 2005-05-11 Sankyo Co MODULATORS OF PPAR (GAMMA)
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
DE60222879T2 (de) * 2001-04-12 2008-07-24 Wyeth Cyclohexylphenyl vasopressin agonisten
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US6977254B2 (en) * 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
DK1381370T3 (da) * 2001-04-12 2007-05-21 Wyeth Corp N-Biphenylcarbonyl- og N-phenylpyridylcarbonyl-substituerede bi- og tricykliske azepiner og diazepiner som vasopressin-agonister
US7064120B2 (en) * 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7326700B2 (en) * 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US7202239B2 (en) * 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0412874D0 (en) * 2004-06-09 2004-07-14 Pfizer Ltd Novel pharmaceuticals
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP2113178A1 (en) 2008-04-30 2009-11-04 Philip Morris Products S.A. An electrically heated smoking system having a liquid storage portion
US8420633B2 (en) * 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) * 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) * 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
RU2623209C9 (ru) * 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP3178510B1 (en) 2011-03-09 2018-08-01 Chong Corporation Medicant delivery system
US8903228B2 (en) 2011-03-09 2014-12-02 Chong Corporation Vapor delivery devices and methods
US9399110B2 (en) 2011-03-09 2016-07-26 Chong Corporation Medicant delivery system
EP2705039B1 (en) * 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
JP5808490B2 (ja) 2011-09-06 2015-11-10 ブリティッシュ アメリカン タバコ （インヴェストメンツ） リミテッドＢｒｉｔｉｓｈ Ａｍｅｒｉｃａｎｔｏｂａｃｃｏ （Ｉｎｖｅｓｔｍｅｎｔｓ） Ｌｉｍｉｔｅｄ 喫煙材の加熱
RU2636649C9 (ru) 2011-09-06 2018-04-06 Бритиш Америкэн Тобэкко (Инвестментс) Лимитед Устройство и способ нагревания курительного материала
CN103288829A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓-5-酮的方法
GB201207039D0 (en) 2012-04-23 2012-06-06 British American Tobacco Co Heating smokeable material
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
BR112014031741B1 (pt) * 2012-06-22 2021-04-27 Sumitomo Chemical Company, Limited Composto de amida, composição e método de controle de peste
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
CN104059070B (zh) * 2013-09-17 2016-02-10 天津药物研究院有限公司 利希普坦晶型ⅰ及其制备方法和用途
CN103755707B (zh) * 2013-09-17 2015-11-18 天津药物研究院 利希普坦晶型ⅱ及其制备方法和用途
CN103694240B (zh) * 2013-09-18 2015-11-18 天津药物研究院 利希普坦的溶剂合物及其制备方法和用途
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
CN104140429B (zh) * 2014-07-25 2015-11-18 天津药物研究院 利希普坦晶型ⅴ及其制备方法和用途
CN104710429B (zh) * 2015-02-04 2017-02-22 浙江大学 手性螺环磷酸催化合成光学活性喹喔啉衍生物的方法
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
US20170119046A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Apparatus for Heating Smokable Material
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
MX2019014475A (es) * 2017-06-09 2020-08-17 Palladio Biosciences Inc Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860600A (en) * 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
ES2056259T3 (es) * 1989-02-10 1994-10-01 Otsuka Pharma Co Ltd Derivados de carboestirilo.
KR0167349B1 (ko) * 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
TW199153B (es) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk
TW198715B (es) * 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
EP0533243B1 (en) * 1991-09-16 1997-12-17 Merck & Co. Inc. Hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives
US5204349A (en) * 1991-09-16 1993-04-20 Merck & Co., Inc. Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
EP0533240A3 (en) * 1991-09-16 1993-09-29 Merck & Co. Inc. Substituted amine derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
EP0533242A3 (en) * 1991-09-16 1993-09-15 Merck & Co. Inc. Substituted derivatives of piperazinylcamphorsulfonyl oxytocin antagonists

Also Published As

Publication number Publication date
PL178563B1 (pl) 2000-05-31
HK1011363A1 (en) 1999-07-09
CZ179994A3 (en) 1995-02-15
CN1205335A (zh) 1999-01-20
DK0636625T3 (da) 1999-09-13
SK280836B6 (sk) 2000-08-14
RU2126006C1 (ru) 1999-02-10
LV12497B (lv) 2000-09-20
HUT71495A (en) 1995-11-28
KR100347479B1 (ko) 2002-12-06
CA2128956C (en) 2004-10-05
FI943543A0 (fi) 1994-07-28
AU6877794A (en) 1995-02-09
CA2128956A1 (en) 1995-01-30
ES2129090T3 (es) 1999-06-01
SG47522A1 (en) 1998-04-17
NO301827B1 (no) 1997-12-15
LV12497A (en) 2000-06-20
NZ264115A (en) 1997-10-24
PH31469A (en) 1998-11-03
US5624923A (en) 1997-04-29
BR1100563A (pt) 2000-02-08
ATE176234T1 (de) 1999-02-15
DE69416211T2 (de) 1999-09-02
US5516774A (en) 1996-05-14
RU94027583A (ru) 1996-07-20
CN1106812A (zh) 1995-08-16
IL110435A0 (en) 1994-10-21
FI20011206A (fi) 2001-06-07
KR950003295A (ko) 1995-02-16
AU683660B2 (en) 1997-11-20
PL304498A1 (en) 1995-02-06
IL110435A (en) 2003-11-23
FI113867B (fi) 2004-06-30
CN1039908C (zh) 1998-09-23
HU220707B1 (hu) 2002-04-29
JP3782475B2 (ja) 2006-06-07
ZA945603B (en) 1995-03-09
ECSP941137A (es) 1995-02-27
FI113868B (fi) 2004-06-30
NO942816L (no) 1995-01-30
FI110944B (fi) 2003-04-30
NO942816D0 (no) 1994-07-28
CN1056374C (zh) 2000-09-13
EP0636625A2 (en) 1995-02-01
EP0636625A3 (en) 1995-05-17
DE69416211D1 (de) 1999-03-11
EP0636625B1 (en) 1999-01-27
SK88194A3 (en) 1995-04-12
CZ291322B6 (cs) 2003-02-12
FI943543A (fi) 1995-01-30
FI20011207A (fi) 2001-06-07
JPH07157486A (ja) 1995-06-20
GR3030069T3 (en) 1999-07-30
HU9402219D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
PE17895A1 (es) Antagonista triciclico diacepinico de vasopresina y antagonista de oxitocina
NZ332605A (en) Tricyclic benzazepine vasopressin antagonists
FI962043A0 (fi) Substituoidut 5-rengas-heterosyklit, niiden valmistus ja niiden käyttö
PL309281A1 (en) Derivatives of 1,4-benzodiazepine and their application as cck modulators
ES2118909T3 (es) Material foto-reactivo.
ATE49211T1 (de) Dreizyklische oxindole als antientzuendungsmittel.
ES2141096T3 (es) Compuestos de cefalosporina y composiciones farmaceuticas de los mismos.
KR950700225A (ko) Cck-수용체 길항제로써 유용한 벤조디아제핀 유도체(benzodiazepin derivatives useful as cck-receptor antagonists)
ES2063157T3 (es) Nuevos derivados del indol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed